ENANTA PHARMACEUTICALS INC
ENTA · XNASCIK 1177648fmd_1A65DBRVD7WJK1W9R05GRE5DS0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2010 to Jun 30, 2026, 60 periods
Latest annual · FY2025
Millions- Total revenues
- 65
- Operating income
- (85)
- Net income
- (82)
- Free cash flow
- (32)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 14
- Operating income
- (17)
- Net income
- (20)
- Free cash flow
- (10)
Daily close · ENTAIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions11.59 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -8.8%
- Revenue, 5 yearsFY2020 to FY2025
- -11.8%
- Net income, 5 yearsFY2020 to FY2025
- n/m
ENANTA PHARMACEUTICALS INC (ENTA) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $65.3 million | $67.6 million | -3.4% | 10-K 2025-11-19 · proof |
| Operating income | -$85.3 million | -$121.7 million | 10-K 2025-11-19 · proof | |
| Net income | -$81.9 million | -$116 million | 10-K 2025-11-19 · proof | |
| Cash from operating activities | -$19.3 million | -$78.8 million | 10-K 2025-11-19 · proof | |
| Free cash flow | -$32.2 million | -$96.7 million | 10-K 2025-11-19 · proof | |
| Total assets | $280.7 million | $376.7 million | -25.5% | 10-K 2025-11-19 · proof |
| Total liabilities | $216 million | $247.8 million | -12.8% | 10-K 2025-11-19 · proof |
| Cash and cash equivalents | $32.3 million | $37.2 million | -13.3% | 10-K 2025-11-19 · proof |
- What was ENANTA PHARMACEUTICALS INC (ENTA)'s revenue in fiscal 2025?
- ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $65.3 million for fiscal 2025 (the year ended Sep 30, 2025), against $67.6 million the year before (-3.4%). Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What was ENANTA PHARMACEUTICALS INC (ENTA)'s operating income in fiscal 2025?
- ENANTA PHARMACEUTICALS INC (ENTA) reported operating income of -$85.3 million for fiscal 2025 (the year ended Sep 30, 2025), against -$121.7 million the year before. Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What was ENANTA PHARMACEUTICALS INC (ENTA)'s net income in fiscal 2025?
- ENANTA PHARMACEUTICALS INC (ENTA) reported net income of -$81.9 million for fiscal 2025 (the year ended Sep 30, 2025), against -$116 million the year before. Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What was ENANTA PHARMACEUTICALS INC (ENTA)'s cash from operating activities in fiscal 2025?
- ENANTA PHARMACEUTICALS INC (ENTA) reported cash from operating activities of -$19.3 million for fiscal 2025 (the year ended Sep 30, 2025), against -$78.8 million the year before. Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What was ENANTA PHARMACEUTICALS INC (ENTA)'s free cash flow in fiscal 2025?
- ENANTA PHARMACEUTICALS INC (ENTA) reported free cash flow of -$32.2 million for fiscal 2025 (the year ended Sep 30, 2025), against -$96.7 million the year before. Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What are ENANTA PHARMACEUTICALS INC (ENTA)'s total assets?
- As of Sep 30, 2025, ENANTA PHARMACEUTICALS INC (ENTA) reported total assets of $280.7 million, against $376.7 million a year earlier (-25.5%). Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What are ENANTA PHARMACEUTICALS INC (ENTA)'s total liabilities?
- As of Sep 30, 2025, ENANTA PHARMACEUTICALS INC (ENTA) reported total liabilities of $216 million, against $247.8 million a year earlier (-12.8%). Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
- What are ENANTA PHARMACEUTICALS INC (ENTA)'s cash and cash equivalents?
- As of Sep 30, 2025, ENANTA PHARMACEUTICALS INC (ENTA) reported cash and cash equivalents of $32.3 million, against $37.2 million a year earlier (-13.3%). Source: the 10-K filed with the SEC on Nov 19, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ENTA&period_type=annual&limit=5"Information only, not investment advice.